BridgeBio LLC
NEWS
FDA has been actively greenlighting a number of efforts over the last few days to push therapies for rare or serious diseases that have largely unmet medical needs. Here’s a look.
The companies will co-finance a clinical study to test the combination of SHP2 inhibitor BBP-398 and OPDIVO in treating patients with advanced solid tumors KRAS mutations.
The FDA approves Truseltiq for patients with previously-treated locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement.
Wang, who has played a key role in the development of more than 25 innovative medicines at Eli Lilly and GlaxoSmithKline, made him the ideal fit for the company’s next chapter.
The transaction between BridgeBio and Eidos is expected to close in the first quarter of 2021.
Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
Biopharma and life sciences strengthen their executive leadership teams and boards with this week’s Movers & Shakers.
With the J.P. Morgan Healthcare Conference in full swing, companies did not waste time in announcing deals and providing updates to their pipelines. BioSpace takes a look at some of the announcements made on day one of the annual conference in the Bay Area.
JOBS
IN THE PRESS